Agenda

Monday, April 15 2019

09:00 am - 09:15 am
Welcome and Opening Remarks

 

 

KEYNOTE ADDRESS

09:15 am - 09:50 am
T-cell co-stimulation in autoimmune diseases and cancer

Arlene H. Sharpe, MD, PhD, Harvard Medical School

 

GASTRONINTESTINAL TOXICITES

SESSION MODERATOR: MICHAEL DOUGAN, MD, PHD

 

09:50 am - 10:10 am
GI Toxicities of Checkpoint Blockade

Michael Dougan, MD, PhD, Massachusetts General Hospital

10:10 am - 10:30 am
Pancreatic Exocrine Related Diarrhea

Erez Baruch, MD, Sheba Medical Center

10:30 am - 10:50 am
Gastrointestinal and Hepatic Complications of Immuno Checkpoint Inhibitors

Robert S. Bresalier, MD, MD Anderson Cancer Center

10:50 am - 11:15 am
PANEL DISCUSSION

 

MOONSHOT ADMINISTRATIVE SUPPLEMENT

AWARDEE UPDATE

11:15 am - 11:35 am
Disruption of T cell tolerance in type 1 diabetes

Mark Anderson, MD, PhD, University of California, San Francisco

11:35 am - 12:50 pm
LUNCH BREAK

 

CYTOKINES, AUTOIMMUNITY, AND IMMUNE RELATED ADVERSE EVENTS REFRACTORY TO INITIAL THERAPY

SESSION MODERATOR: ELAD SHARON, MD, MPH

12:00 am - 01:10 pm
IVIG vs. Inflixumab - steroid refractory pneumonitis

Jarushka Naidoo, MBBCh, Johns Hopkins University

01:10 pm - 01:30 pm
Multidisciplinary irAE models

Kelly Walkovich, MD, C. S. Mott Children’s Hospital

01:30 pm - 01:50 pm
Balancing immune tolerance with low-dose IL-2

David Klatzmann, MD, PhD, Hôpital Pitié-Salpêtrière, Sorbonne Université

 

01:50 pm - 02:15 pm
PANEL DISCUSSION

 

NEUROLOGICAL AND OCULAR TOXICITIES

SESSION MODERATOR: DAVID HAFLER, MD, FANA

02:15 pm - 02:35 pm
Unleashing the immune system in the brain

David Hafler, MD, FANA, Yale School of Medicine

02:35 pm - 02:55 pm
Neurotoxicity associated with immune checkpoint inhibitor treatment

Bianca D. Santomasso, MD, PhD, Memorial Sloan Kettering Cancer Center

02:55 pm - 03:15 pm
Ocular Toxicities

Hatice Nida Sen, MD, MHS, National Eye Institute

03:15 pm - 03:40 pm
PANEL DISCUSSION
03:40 pm - 04:00 pm
BREAK

 

 

 

KEYNOTE ADDRESS

04:00 pm - 04:30 pm
IO combination clinical trials

Elizabeth M. Jaffee, MD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

 

COMBINATION THERAPIES

SESSION MODERATOR: ELIZABETH JAFFEE, MD

04:30 pm - 04:50 pm
Keynote presentation: IO combination clinical trials

Elizabeth M. Jaffee, MD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

04:10 pm - 04:30 pm
Toxicities of radiation-immunotherapy combinations

Jonathan D. Schoenfeld, MD, MPhil, MPHD, Dana-Farber Cancer Institute

04:50 pm - 05:10 pm
Regulatory perspective

Nicole Drezner, MD, U.S. Food and Drug Administration

05:10 pm - 05:35 pm
PANEL DISCUSSION
05:35 pm - 07:00 pm
POSTER SESSION & RECEPTION

 

ADJOURN

Tuesday, April 16 2019

09:00 am - 09:05 am
Welcome and Tribute to Stephen Katz

 

SKIN TOXICITIES AND RHEUMATOLOGY 

SESSION MODERATOR: ROBERT CARTER, MD

09:05 am - 09:25 am
Rheumatic adverse effects of immune checkpoint inhibitors

Xavier Mariette, MD, PhDHôpital Bicêtre, Université Paris-Sud

09:25 am - 09:45 am
Sicca as a complication of immune checkpoint inhibition: Is it Sjögren’s Syndrome?

 Blake Warner, DDS, PhD, MPH, National Institute of Dental and Craniofacial Research

09:45 am - 10:05 am
Skin toxicities from immune checkpoint inhibitors

Nicole LeBoeuf, MD, MPH, Dana-Farber Cancer Institute

10:05 am - 10:25 am
Mechanisms of autoimmunity association with cancer

Antony Rosen, MBChB, MD, Johns Hopkins Medicine

10:25 am - 10:50 am

 

PANEL DISCUSSION

10:50 am - 11:10 am

 

BREAK

 

MOONSHOT ADMINISTRATIVE SUPPLEMENT

AWARDEE UPDATE

11:10 am - 11:35 am
Regulation and function of nonlymphoid organ CD103 dendritic cells

Stephanie Watowich, PhD, MD Anderson Cancer Center

 

THE BIG PICTURE: APPROACHING IMMUNE-RELATED ADVERSE EVENTS FROM MULTIPLE DATA STREAMS

SESSION MODERATOR: GIORGIO TRINCHIERI, MD

 

11:35 am - 11:55 am
Immune-related adverse events

Douglas B. Johnson, MD, Vanderbilt-Ingram Cancer Center

11:55 am - 12:15 pm
Alliance-NCI immune-related adverse events biorepository

David Kozono, MD, PhD, Dana Farber Cancer Institute

12:15 pm - 12:35 pm
Regulatory perspective

Meredith Chuk, MD, U.S. Food and Drug Administration

12:35 pm - 01:45 pm

 

LUNCH BREAK

 

KEYNOTE ADDRESS

01:45 pm - 02:15 pm
The role of the microbiome in response and toxicity to cancer therapy

Jennifer Wargo, MD, MMSc, MD Anderson Cancer Center

 

02:15 pm - 02:45 pm

 

PANEL DISCUSSION

 

 

CELL-BASED IMMUNOTHERAPY

02:45 pm - 03:10 pm
Adverse events of CAR-T cell therapy for hematologic malignancies

David L. Porter, MD, University of Pennsylvania Perelman School of Medicine

03:10 pm - 03:35 pm
CAAR-T for pemphigus vulgaris

Michael Milone, MD, PhD, University of Pennsylvania Perelman School of Medicine

03:35 pm - 03:55 pm

 

BREAK

 

NON-CLINICAL MODELS

SESSION MODERATORS:

JOHN LEIGHTON, PHD AND JULIE SCHNEIDER, PHD  

 

03:55 pm - 04:15 pm
Autoimmunity following cancer treatment, more questions than answers

Jeff Bluestone, PhD, Parker Institute for Cancer Immunotherapy

04:15 pm - 04:35 pm
Evaluating IO toxicities in syngeneic immunocompetent mouse models: Lessons, opportunities and challenges

Gregory L. Beatty, MD, PhD, University of Pennsylvania

04:35 pm - 04:55 pm
Preventing immunotherapy related adverse events by targeting CD24-Siglec signaling pathway

Pan Zheng, MD, PhD, University of Maryland, Baltimore

04:55 pm - 05:15 pm
Immune-mediated adverse events in humanized mice receiving checkpoint inhibitors

Kristina E. Howard, DVM, PhD, U.S. Food and Drug Administration

05:15 pm - 05:45 pm

 

PANEL DISCUSSION

 

WRAP-UP AND ADJOURN